SCHEMBL23966710

SCHEMBL23966710

CN1CCN(Cc2cc(C(C)(C)C)on2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 2/20 0.46
FLT3 P36888 4/20 0.45
CSF1R P07333 1/20 0.45
AURKA O14965 4/20 0.40
EGFR P00533 2/20 0.40
KCNH2 Q12809 2/20 0.40
KDR P35968 3/20 0.40
ALK Q9UM73 3/20 0.40
BRD4 O60885 1/20 0.39
MC4R P32245 1/20 0.39
AURKB Q96GD4 1/20 0.38
AURKC Q9UQB9 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
TDP1 Q9NUW8 1/20 0.37
GAA P10253 2/20 0.37
TSHR P16473 2/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13559779 0.78 AURKA (0.53) KDM4EALDH1A1MAPTFLT3AURKA
SCHEMBL23966717 0.76 EGFR (0.36) EGFRTSHRHPGD
SCHEMBL23966744 0.75 MC4R (0.40) KDM4EALDH1A1MAPTAURKAKCNH2
SCHEMBL25796945 0.75 HSP90AA1 (0.41) KDM4EALDH1A1MAPTAURKAKCNH2
SCHEMBL25792446 0.75 HPGD (0.38) EGFRHPGD
SCHEMBL19598492 0.74 EGFR (0.38) FLT3CSF1REGFRKCNH2HPGD
SCHEMBL23966639 0.72 MEN1 (0.37) FLT3CSF1REGFRHRH4
SCHEMBL9610944 0.71 MEN1 (0.44) ALDH1A1EGFRLMNAPOLBHPGD
SCHEMBL25910304 0.71 KDM4E (0.38) KDM4EALDH1A1MAPTAURKAKCNH2
SCHEMBL2733286 0.70 EGFR (0.45) ALDH1A1EGFRLMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 KDM4E 1783/4885ALDH1A1 4327/4885MAPT 1175/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 KDM4E 1778/4885ALDH1A1 4354/4885MAPT 1210/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 KDM4E 4052/4885ALDH1A1 4542/4885MAPT 436/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 KDM4E 1778/4885ALDH1A1 4354/4885MAPT 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.